StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — CLSA

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byCLSAHorizon: NA (inferred 1 year)10 Jul 2026via Zee Business (Live)

Entry₹1,244.9Inferred
Target₹1,570
Total upside +26.11%
Stop lossNot given
CMP₹1,229.52d ago
Active-1.24%+27.69%upside left 9 mo left
Follow CLSA for new calls(100% target hit, 24 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 18 other Long-term calls on DRREDDYSee 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:33 pm IST
17 supporting9 neutral14 opposing
Supports the BUY call (17)

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 4d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 4d ago

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 4d ago

(opens in new tab)

9 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·7 Oct · 3w ago

Citi raises target for Dr Reddy's Laboratories stock to INR 1,450

NewsGoogle News·2 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (9)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 2d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 6d ago

(opens in new tab)
Weighs against the BUY call (14)

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 2d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 2d ago

(opens in new tab)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·23 Oct · 2d ago

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 2w ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from CLSA

Every call and its outcome